Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.72 +0.44 (+0.90%)
Streaming Delayed Price Updated: 3:58 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
31 32 Next >
Earnings Scheduled For July 28, 2023
Companies Reporting Before The Bell • Sanofi (NASDAQ:SNY) is likely to report quarterly earnings at $1.58 per share on revenue of $11.32 billion. 
Via Benzinga
Sanofi's Earnings Outlook
Via Benzinga
Exscientia is the Sniper of the AI Drug Discovery Industry
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
How Is The Market Feeling About Sanofi?
Via Benzinga
Looking Into Sanofi's Recent Short Interest
Via Benzinga
Novo Nordisk's Diabetes, Weight Loss Drugs Under UK Scrutiny: Follows Suicidal Behavior Reports
The Medicines and Healthcare Products Regulatory Agency (MHRA), the U.K.'s drug regulatory authority, is reportedly scrutinizing a category of drugs used in diabetes medication and a weight loss... 
Via Benzinga
7 Blue-Chip Stocks That Are Screaming Buys Right Now: July 2023
Even some of the top players of the market don’t get the attention they deserve, making these blue-chip stocks compelling. 
Via InvestorPlace
Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
From Recludix Pharma, Inc.
Via GlobeNewswire
NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories
Wall Street Journal 
Via Benzinga
2 Biopharma Stocks Making Big Moves Tuesday
Markets looked poised for a pause, but these stocks didn't stand still. 
Via The Motley Fool
2 Best Biotech Stocks to Buy Right Now
These international-based pharmaceutical companies pay market-topping dividends to shareholders. 
Via The Motley Fool
AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants
The FDA approved AstraZeneca Plc (NASDAQ: 
Via Benzinga
Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment
Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in... 
Via Benzinga
Is Affordable Insulin Available? Survey Reveals Uninsured Americans Paying More Despite Promised Price Reduction
According to a survey conducted by U.S. 
Via Benzinga
Why Shares of Exscientia Jumped on Wednesday
The company may be riding the wave of an AI healthcare boom. 
Via The Motley Fool
Takeda Withdraws FDA Application For Dengue Vaccine Candidate On Data Disagreement
Takeda Pharmaceutical Co Ltd (NYSE: TAK) said on Tuesday that it was voluntarily  
Via Benzinga
Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA)
Tiziana Life Sciences (NASDAQ: TLSA) is a biotechnology company establishing itself in a cutting-edge position in the market with its breakt 
Via Benzinga
Evotec Secures US Government Contract For Orthopoxvirus Antibody
The U.S. 
Via Benzinga
First US Trial Over Zantac's Alleged Cancer-Causing Properties Set For November In California
The initial U.S. court trial concerning the antacid medication Zantac is slated to commence on November 13 in a state court in California, as stated by a lawyer representing the plaintiffs. 
Via Benzinga
Sanofi's Amlitelimab Hits Primary Goal In Mid-Stage Atopic Dermatitis Study
Sanofi SA (NASDAQ: SNY) says its Phase 2b study (STREAM-AD) of amlitelimab for adults with moderate-to-severe atopic dermatitis, who cannot adequately manage their condition with topical medications,... 
Via Benzinga
AI Stocks: C3.ai, Palantir Pull Back Amid HPE, Cybersecurity, Cloud AI News
The big rally in AI stocks may finally be taking a break but the steady drumbeat in artificial intelligence news continues. 
Via Investor's Business Daily
GSK Confidentially Settles First Zantac-Associated Cancer Lawsuit Due For US Trial Next Month
GSK plc (NYSE: GSK) has reached a confidential settlement with James Goet 
Via Benzinga
European Drug Authority Raises Thyroid Cancer Safety Signal For Novo Nordisk Drugs, Including Hyped Semaglutide
The EU's drugs watchdog, the European Medicines Agency, recently raised a thyroid cancer safety signal for Novo Nordisk A/S (NYSE: NVO) drugs, including the much talked semaglutide used i 
Via Benzinga
Spotify to Launch New Expensive Subscription Plan, Chinese Vendors Bypass US Embargo to Supply Nvidia AI Chips, Eddie Wu To Succeed Daniel Zhang As Alibaba's CEO: Today's Top Stories
Bloomberg 
Via Benzinga
Sanofi Stock Is Trading Higher Today - Here's Why
Sanofi SA (NASDAQ: SNY) announced that the tribunal dismissed Boehringer Ingelheim's indemnification claim against Sanofi in an International Chamber of Commerce dispute in cancer lawsuits linked to... 
Via Benzinga
Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company?
Company Moves Ahead With Drug Development 
Via Benzinga
DarioHealth is an AI-Powered Digital Therapeutics Play
DarioHealth Co. (NASDAQ: DRIO) is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for chronic 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Netflix Gains Subs From Password Sharing Crackdown, Mark Zuckerberg Discusses AI at Latest Employee Met, Privacy Breach Risk in Nvidia's AI Technology Stirs Concern: Today's Top Stories
Financial Times 
Via Benzinga
Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t 
Via Benzinga
Why Shares of Innate Pharma Jumped Thursday
The company's collaboration agreement with Sanofi could soon pay off. 
Via The Motley Fool
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.